We are excited to share that Biocytogen will be exhibiting at the Festival of Biologics from October 13th - 15th in Basel, Switzerland. Bringing together over 3,000 global attendees, it is one of Europe’s largest conferences focused on biologics. Our experts will be at booth 345, sharing our latest available mouse models and how they support biologics discovery and preclinical research across antibody, cell and gene therapy, and immunotherapy programs.
What is Festival of Biologics 2026?
The Festival of Biologics’ event program highlights the latest developments and findings across antibody therapies, cell and gene therapies, immunotherapies, and biosimilars. Discover what’s next in biologics, gain fresh perspectives, and connect with the people shaping the future of advanced therapies.
Event Overview
Date: October 13th - 15th, 2026
Venue: Messe Basel, Messepl. 10, 4005 Basel, Switzerland
Booth: 345
Posters
A Novel CDH17-Targeting CD3xCD28 Trispecific T-Cell Engager Demonstrates Potent Anti-Tumor Activity against Colorectal Cancer in Preclinical Models
BCG051: A First-in-Class Bispecific Antibody Targeting GDF-15 and VEGFA to Synergistically Inhibit Tumor Growth and Reverse Cancer-Associated Cachexia
Preclinical Evaluation of T-Cell Engager Therapies Using Humanized CD3EDG/FOLR1/FOLR2 Mice
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
